1 Report on twinning short visit within the WP1 Task 1.11 of BASTION project Science Business, Feb 2015, Brussels Karolina Dzwonek Jakub Golab
2 Jakub Golab, BASTION project coordinator and Karolina Dzwonek, Innovation Manager, during their short visit at Science Business in February discussed current issues concerning MUW- Science Business collaboration. Karolina Dzwonek at the entrance to Science Business office Together with Science Business management they discussed the remaining project tasks of Science Busienss experts. It appeared that there was a need to modify the tasks of Ms Gail Edmondson so BASTION team members proposed the following amendment to the contract signed on by and between the Medical University of Warsaw, and Ms Gail Edmondson: Subtask 1(15 working days in total) is being changed into: preparation of guidelines for Medical University of Warsaw for efficient technology transfer and IP management, based on KULeuven and university s technology transfer office - KU Leuven Research & Development (LRD) history and best practices. The expert will take an interview with the Rector of KULeuven and one of the leaders of the LRD in order to identify strategies, solutions and management schemes that could be implemented by MUW authorities in order to facilitate translational research at the university. These guidelines could be used by MUW authorities in setting up the technology transfer unit within the structure of the university, financing it at the beginning of its activity, engaging the right human resources, building relations (inside the university and outside - identifying key partners). The expert will present a case study of successful commercialization of a technology developed at KULeuven, pointing key success factors of the enterprise. The new subtask 1will be submitted in a form of a report, that includes two interviews, the summary of KULeuven technology transfer experience, guidelines for MUW authorities and a case study. During the meeting BASTION team members discussed with Science Business upcoming event Pharma Day 2015, to be organized within WP5 in the Spring The following list of participants was proposed: 1. Andrzej Bialkowski-Miler, BM Consulting 2. Marta Borkowska, Oncoarendi Therapeutics 3. Bruno Botta Sapienza, University of Rome 4. Krzysztof Brzozka, Selvita 5. Janusz Bujnicki, International Institute of Molecular and Cellular Biology
3 6. Agnieszka Byszek, Cancer Center and Institute of Oncology 7. Magdalena Chechlińska, Cancer Center and Institute of Oncology 8. Tomasz Ciach, Warsaw University of Technology 9. Marcin Ciuk, Nencki Institute of Experimental Biology 10. Bruce Conway, Rockefeller University 11. Iwona Cymerman, Nanovelos 12. Wojciech Czardybon, Selvita 13. Anna Czarnecka, Military Institute of Medicine 14. Janusz Debski, Institute of Biochemistry and Biophysics 15. Ewa Debudaj, Medical University of Warsaw BASTION 16. Iwona Drozdowska, Medical University of Warsaw BASTION 17. Andrzej Dziembowski, Institute of Biochemistry and Biophysics 18. Artur Dzwonek, Medical University of Warsaw 19. Karolina Dzwonek, Medical University of Warsaw BASTION 20. Anna Fogler, Medical University of Warsaw BASTION 21. Zbigniew Gaciong, Medical University of Warsaw BASTION 22. Paweł Gaj, Medical University of Warsaw BASTION 23. Jakub Golab, Medical University of Warsaw BASTION 24. Leszek Grabarczyk, National Center for Research and Development 25. Slawomir Gruca, Medical University of Warsaw BASTION 26. Henryk Gruza, FDFPHARMA 27. Duncan Holmes, GlaxoSmithKline 28. Magdalena Janczewska, Warsaw University of Technology 29. Radosław Jazwiec, Institute of Biochemistry and Biophysics 30. Przemyslaw Juszczynski, Institute of Hematology and Transfusion Medicine 31. Bozena Kaminska, Nencki Institute of Experimental Biology 32. Piotr Kaminski, Kaminski& Partners Patent and Trademark Attorneys 33. Joanna Kinasiewicz, Institute of Biocybernetics and Biomedical Engineering 34. Malgorzata Kolodziejczyk-Mierzynska, Medical University of Warsaw 35. Michał Konieczny, Merck 36. Tomasz Korkosz, Pfizer 37. Magdalena Kowalewska, Medical University of Warsaw 38. Katarzyna Koziak, Medical University of Warsaw 39. Magdalena Krol, Medical University of Warsaw BASTION 40. Leszek Krolicki, Medical University of Warsaw 41. Olga Krylova, Pfizer 42. Adam Krzystyniak, Nencki Institute of Experimental Biology 43. Aleksandra Kulikowska, Warsaw University of Technology 44. Andrzej Kusmierz, Idea2Business 45. Monika Lamparska-Przybysz, Polpharma SA 46. Joanna Lipner 47. Piotr Lutostanski, Echo Investments 48. Iwona Lugowska, Cancer Center and Institute of Oncology 49. Slawomir Majewski, Medical University of Warsaw BASTION 50. Marcin Makowski, Astra Zeneca 51. Marcin Mazurkiewicz, Nencki Institute of Experimental Biology
4 52. Shane McCollam, Science Business 53. Danuta Mossakowska, GlaxoSmithKline 54. Karolina Niewiadomska, Warsaw City Hall 55. Dominika Nowis, Medical University of Warsaw BASTION 56. Marcin Nowotny, International Institute of Molecular and Cellular Biology 57. Jerzy Pieczykolan 58. Stanislaw Pikul, Oncoarendi Therapeutics 59. Paulina Podszywałow-Bartnicka, Nencki Institute of Experimental Biology 60. Ewa RutkowskaKieszkowska, RutkowskaKolasiński 61. Izabela Rzepczynska, National Center for Research and Development 62. Janusz Siedlecki, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology 63. Piotr Sklepkiewicz, Oncoarendi Therapeutics 64. DariuszSmolen, BioTechMed cluster 65. Agata Stefanek, Warsaw University of Technology 66. Filip Stefaniak, International Institute of Molecular and Cellular Biology 67. Tomasz Stokłosa, Medical University of Warsaw BASTION 68. Robert Swider, Medical University of Warsaw 69. Marcin Szumowski, Oncoarendi Therapeutics 70. Magdalena Tagowska, Patpol 71. Robert Verhagen, Helix Biopharma 72. Maciej Wierzbicki, BioTechMed cluster 73. Pawel Wisniewski, Inagen 74. Michal Wojasinski, Warsaw University of Technology 75. Agnieszka Zagozdzon, Oncoarendi Therapeutics 76. Radoslaw Zagozdzon, Medical University of Warsaw BASTION 77. Ewa Zalewska, Institute of Biocybernetics and Biomedical Engineering 78. Daria Zdzalik, International Institute of Molecular and Cellular Biology 79. Anna Zdziarska, Oncoarendi Therapeutics 80. Florin Zubascu, Science Business 81. Aldona Zygmunt, Pfizer 82. Agnieszka Zebrowska, Patpol Also the preliminary agenda of the event was discussed and the following draft was prepared: Pharma Day preliminary program (April 24th) Keynote: Bruce Conway - From drug discovery to market: case study from J&J Science for drug discovery: Prof. Jakub Golab (Medical University of Warsaw) to talk about molecular targets for immunotherapy of cancer prof. LeszekKrolicki (Medical University of Warsaw) &Prof. Ewa Zalewska (Institute of Biocybernetics and Biomedical Engineering) about new imaging methods in cancer diagnosis and for monitoring
5 efficacy of treatment (and capabilities of new Centre for Integrated Structural and Functional Studies of the Central Nervous System) Prof. Bruno Botta (Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma) GlaB: The Reward for Perseverance Prof. Andrzej Dziembowski (Institute of Biochemistry and Biophysics) about synthetic lethality as a therapeutic approach in multiple myeloma treatment dr Marcin Nowotny (International Institute of Molecular and Cellular Biology) about crystallography in drug discovery Short Discussion Panel How to make industry - science collaboration in early stage drug discovery programs more productive? Discussants: dr Bruce Conway, Selvita, Prof. Bruno Botta, dr Maciej Wierzbicki (BTM cluster) Innovative drug discovery programs in Poland: dr Krzysztof Brzozka/dr Wojciech Czardybon (VP & CSO at Selvita) about PIM/Flt3 dual inhibitor drug discovery program dr Marcin Szumowski (CEO at OncoArendi Therapeutics) about the model of collaboration with academia dr Iwona Ługowska (Cancer Center and institute of Oncology) about phase I clinical trials center with Adamed Big Pharma and Academia collaboration model Duncan Holmes (GSK Discovery Partnerships with Academia) about DPAc program Closing discussion panel: Role of Academic researchers, small to midsize biotech and big pharma in translational drug discovery process in oncology. Duncan Holmes (GSK), Polpharma, Astra Zeneca and any other potential pharmaceutical companies.
more information on www.pharma-industry.pl Programme Board: Grzegorz Cessak President of the Offi ce for Registration of Medicinal Products, Medical Devices and Biocidal Products Andrzej Szarmański President
2 ND There has never been a conference solely dedicated to addressing the needs of due diligence and licensing professionals. As far as I m concerned, this is a must attend BUSINESS DEVELOPMENT, PFIZER
WARSAW www.telekomunikacjaimedia.pl ABOUT CONGRESS Warsaw International Media Summit for it s 8 years of history became the one of the most important events for Poland s media sector. The Congress successfully
Authored by: Cynthia Duggan Associate Director, Alzheimer's Disease and Dementia Initiative, The New York Academy of Sciences Drew Holzapfel Executive Director, The Global CEO Initiative on Alzheimer s
2011 Innovation Centers in Poland Directory of innovative business support institutions technology parks technology incubators technology transfer centers The Polish Agency for Enterprise Development ul.
Cite as: NAICS Appeal of Information Ventures, Inc., SBA No. NAICS-4882 (2008) United States Small Business Administration Office of Hearings and Appeals NAICS APPEAL OF: Information Ventures, Inc. Appellant
CATALOGUE 2008 OF THE WINNERS 12 th EDITION OF THE POLISH PRODUCT OF THE FUTURE COMPETITION Polish Agency for Enterprise Development is not responsible for the content of projects description. Detailed
TRANSFER IN THE MEDICAL SECTOR FROM CLINICS TO COMPANIES Content: Editorial - P.1 Cooperation of the CE Programme - P.1 Meetings - Project Meeting in Linz, Austria; Workgroup meeting in Hohenkammer, Germany
JD/MS in Biochemistry Dual Degree Proposal This document contains a proposal for a dual degree between the Department of Biochemistry (MS degree) and the School of Law (JD degree). Justification Intellectual
Clinically competitive: Boosting the business of clinical trials in Australia Clinical Trials Action Group Report Commonwealth of Australia 2011 ISBN 978-0-642-72616-2 This work is copyright. Apart from
BIONOMICS IS A LEADING INTERNATIONAL DRUG DISCOVERY AND DEVELOPMENT COMPANY BREAST CANCER BEFORE BNC105 TREATMENT BREAST CANCER AFTER BNC105 TREATMENT LIFE TRANSFORMING TREATMENTS FOR CANCER AND CNS DISORDERS
Professional Legal Solutions for Businesses Financial, Capital Markets and Innovative Legal Solutions for Business Table of Contents Firm Profile 1 Project Financing 2 Bank Lending 3 Derivatives and Structured
Putting it All Together: A Strategy for Special Needs Services that Make Sense for Families Information Session Ministry of Children and Youth Services Ministry of Community and Social Services Ministry
Big Data & Life Sciences Acknowledgments The Mass Technology Leadership Council is grateful for the leadership and support that Governor Deval Patrick has provided to the region s big data ecosystem with
Priority III: A National Cyberspace Security Awareness and Training Program Everyone who relies on part of cyberspace is encouraged to help secure the part of cyberspace that they can influence or control.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
EXECUTIVE PROGRAMME OF SCIENTIFIC AND TECHNOLOGICAL CO-OPERATION BETWEEN THE ITALIAN REPUBLIC AND THE REPUBLIC OF POLAND 2004-2006 XVIII Session of Italian Polish Joint Commission Rome, April 29-30, 2004
Professional Legal Solutions for Businesses Your Full Scope IP Law Practice Table of Contents Our Firm 1 Industrial Property Administration 2 IP SCOUT Revolutionary Solution for IP Administration 3 Technology
Understanding the Clinical Research Process and Principles of Clinical Research Participant Guide Name INTRODUCTION... 1 What Is AIDS?...1 What Is the History of AIDS?...2 What Are the Division of AIDS
10 June 2014 CANCER CONTROL STRATEGY FOR POLAND 2015-2024 Project Coordinator Office of the Project we should think big, act small, dare to fail, stop talking and start acting NOW Lucien Engelen 3 4 Contents
ANNUAL REPORT 2013 the of Product Pipeline MorphoSys s Product Pipeline, as of 31 December 2013 Program Partner Indication Phase 1 Phase 2 Phase 3 Market MOR103 GSK Rheumatoid arthritis Multiple sclerosis
Benefits of Collaborative Finance Research in Business Schools Robert Kao, PhD Assistant Professor of Finance, School of Business Park University Collaboration in business research provides outcomes and
Catalonia Life Sciences Report 2011 2 Contents Chapter 1 Preface 4 Chapter 2 Scope of the report 8 Chapter 3 Introduction to the Catalonia Life Sciences Sector 10 Chapter 4 National and International Benchmarking
EVALUATION GUIDE FCT Evaluation of R&D Units 2013 31 July 2013 Contents 1. Introduction... 4 FCT mission... 4 Funding of R&D Units... 4 2. 2013 Evaluation of R&D Units... 6 Objectives and main criteria...
ASSESSMENT REPORT April 23, 2014 Document History This document is controlled through the Document Management Process. To verify that the document is the latest version, please contact the First Data team.